In Brief: Gynecare
This article was originally published in The Gray Sheet
Gynecare: Files 510(k) with FDA for its bipolar vaporization system for uterine fibroid removal. The minimally invasive system incorporates a "novel, electro-vaporization technology" that utilizes saline as an irrigation fluid, Gynecare says. Saline "is considered to be the optimal medium for hysteroscopic procedures because it does not affect normal blood chemistry" like sorbitol or glycine, used in traditional monopolar myomectomy procedures, the company adds. Gynecare estimates that fibroids account for approximately 180,000 (roughly 30%) of hysterectomy procedures annually in the U.S...
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.